JP2012528099A - Plk1阻害剤および抗腫瘍剤を含む治療組合せ - Google Patents
Plk1阻害剤および抗腫瘍剤を含む治療組合せ Download PDFInfo
- Publication number
- JP2012528099A JP2012528099A JP2012512317A JP2012512317A JP2012528099A JP 2012528099 A JP2012528099 A JP 2012528099A JP 2012512317 A JP2012512317 A JP 2012512317A JP 2012512317 A JP2012512317 A JP 2012512317A JP 2012528099 A JP2012528099 A JP 2012528099A
- Authority
- JP
- Japan
- Prior art keywords
- combination
- combination according
- agent
- inhibitor
- alkylating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
欧州共同体理事会ディレクティブno.86/609/EECにしたがって、Harlan(Italy)からのBalb、Nu/Nuオスのマウスを、ろ紙カバー、餌、滅菌した寝床、酸性化した水を備えたケージ中に保持した。HT29ヒト結腸癌腫瘍の断片を皮下に埋め込んだ。腫瘍が触診可能になったら治療を開始した。式(I)の化合物を、2日、3日、4日、6日、7日および8日目に日に45mg/kgの用量で経口経路により投与し、5FUを、1日、5日および9日目に50mg/kgの用量で静注経路により投与した。併用の場合、式(I)の化合物を2日、3日、4日、6日、7日および8日目に投与し、5−FUを1日、5日および9日目に投与した。腫瘍成長および体重を3日ごとに測定した。腫瘍成長をノギスで評価した。2つの直径を記録し、腫瘍重量を、以下の式:長さ(mm)×幅2/2にしたがって算出した。抗腫瘍治療の効果を、腫瘍の指数関数的成長の開始の遅れで評価した(例えばAnticancer drugs 7:437−60頁、1996年を参照されたい)。この遅れ(T−C値)を、治療群(T)と対照群(C)の腫瘍が所定サイズ(1g)に到達するのに要する時間の差(日で)と定義した。薬物併用のT−Cが単一薬剤のT−C値を加算したものより大きいとき相乗性が確認され、薬物併用のT−C値が単一薬剤のT−C値の加算値と等しいとき加算性が確認された。体重減少をもとにして毒性を評価した。結果を表11に報告する。
Claims (25)
- 代謝拮抗剤が、5−フルオロウラシル、アザシチジン、カペシタビン、シタラビン、ゲムシタビン、ペメトレキセド、メトトレキサート、エダトレキサート、ヒドロキシウレア、フルダラビンおよびメルカプトプリンからなる群から選択される、請求項1に記載の組合せ。
- 代謝拮抗剤が、ゲムシタビンまたはシタラビンである、請求項2に記載の組合せ。
- アルキル化剤またはアルキル化様薬剤が、ナイトロジェンマスタード(メクロレタミン、シクロホスファミド、イホスファミド、メルファランおよびクロラムブシル)、アジリジン(チオテパ)、ニトロソウレア(カルムスチン、ロムスチン、セムスチン)、トリアゼン(ダカルバジンおよびテモゾロマイド)および白金誘導体(シスプラチン、オキサリプラチン、カルボプラチンおよびサトラプラチン)からなる群から選択される、請求項1に記載の組合せ。
- アルキル化剤またはアルキル化様薬剤がシスプラチンである、請求項4に記載の組合せ。
- 挿入剤がブレオマイシンである、請求項1に記載の組合せ。
- トポイソメラーゼI阻害剤が、トポテカン、SN−38、CPT11および9−ニトロカンプトテシンからなる群から選択される、請求項1に記載の組合せ。
- トポイソメラーゼI阻害剤がSN−38またはCPT11である、請求項7に記載の組合せ。
- トポイソメラーゼII阻害剤が、ドキソルビシン、エピルビシン、イダルビシン、ネモルビシン、ミトキサントロン、エトポシドおよびテニポシドからなる群から選択される、請求項1に記載の組合せ。
- トポイソメラーゼII阻害剤がドキソルビシンである、請求項9に記載の組合せ。
- 抗有糸分裂剤が、パクリタキセル、ドセタキセル、イクサベピロン、ビンブラスチン、ビンクリスチン、ビンデシンおよびビノレルビンからなる群から選択される、請求項1に記載の組合せ。
- 抗有糸分裂剤がパクリタキセルである、請求項11に記載の組合せ。
- キナーゼ阻害剤が、ソラフェニブ、ダサチニブ、ゲフィチニブ、エルロチニブ、スニチニブ、イマチニブ、ニロチニブおよびラパチニブからなる群から選択される、請求項1に記載の組合せ。
- キナーゼ阻害剤がソラフェニブまたはダサチニブである、請求項13に記載の組合せ。
- プロテアソーム阻害剤がボルテゾミブである、請求項1に記載の組合せ。
- 成長因子またはその受容体を阻害する抗体が、ベバシズマブ(血管内皮成長因子に対する抗体)、セツキシマブ、パニツムマブ、マツズマブ、ニモツズマブ(表皮成長因子受容体に対する抗体)、トラスツズマブおよびペルツズマブ(ErbB2に対する抗体)からなる群から選択される、請求項1に記載の組合せ。
- 成長因子またはその受容体を阻害する抗体がベバシズマブである、請求項16に記載の組合せ。
- 請求項1から17のいずれか一項に記載の組合せを薬学的に許容される担体、希釈剤または賦形剤と一緒に含む医薬組成物。
- 同時、別個または逐次使用するための、請求項1から17のいずれか一項に記載の組合せまたは請求項18に記載の医薬組成物。
- 請求項1から17のいずれか一項に記載の組合せの治療有効量を、それを必要とする患者に同時、逐次または別個に投与することを含む、増殖性疾患を治療するまたはその進行を遅延させる方法。
- (a)請求項1に記載の式(I)の化合物、ならびに(b)代謝拮抗剤、アルキル化剤またはアルキル化様薬剤、挿入剤、トポイソメラーゼIまたはII阻害剤、抗有糸分裂剤、キナーゼ阻害剤、プロテアソーム阻害剤および成長因子またはその受容体を阻害する抗体からなる群から選択される1つ以上の抗腫瘍剤を、それを必要とする患者に、同時、逐次または別個に投与することを含む増殖性疾患の治療方法。
- 請求項1に記載の式(I)の化合物、ならびに代謝拮抗剤、アルキル化剤またはアルキル化様薬剤、挿入剤、トポイソメラーゼIまたはII阻害剤、抗有糸分裂剤、キナーゼ阻害剤、プロテアソーム阻害剤および成長因子またはその受容体を阻害する抗体からなる群から選択される1つ以上の抗腫瘍剤を含む組合せ製剤を、相乗的抗腫瘍効果をもたらすのに有効な量でそれを必要とする、ヒトを含む哺乳動物に投与することを含む、哺乳動物において抗腫瘍剤を用いて抗腫瘍治療することによって引き起こされる副作用を低減させる方法。
- 同時、別個または逐次使用のための、請求項1に記載の組合せまたは請求項18に記載の医薬組成物を適切な容器手段中に含む市販用キット。
- 増殖性疾患を治療するまたはその進行を遅延させるのに使用するための、請求項1に記載の組合せまたは請求項18に記載の医薬組成物。
- 増殖性疾患を治療するまたは遅延させるための、医薬品の調製における請求項1に記載の組合せまたは請求項18に記載の医薬組成物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09161111.1 | 2009-05-26 | ||
EP09161111 | 2009-05-26 | ||
PCT/EP2010/057027 WO2010136394A1 (en) | 2009-05-26 | 2010-05-21 | Therapeutic combination comprising a plk1 inhibitor and an antineoplastic agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012528099A true JP2012528099A (ja) | 2012-11-12 |
JP5785157B2 JP5785157B2 (ja) | 2015-09-24 |
Family
ID=42806010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012512317A Active JP5785157B2 (ja) | 2009-05-26 | 2010-05-21 | Plk1阻害剤および抗腫瘍剤を含む治療組合せ |
Country Status (7)
Country | Link |
---|---|
US (1) | US8927530B2 (ja) |
EP (1) | EP2435041B1 (ja) |
JP (1) | JP5785157B2 (ja) |
AR (1) | AR076784A1 (ja) |
ES (1) | ES2617689T3 (ja) |
TW (1) | TW201107327A (ja) |
WO (1) | WO2010136394A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011505403A (ja) * | 2007-12-04 | 2011-02-24 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 置換ジヒドロプテリジン−6−オン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用 |
JP2013500299A (ja) * | 2009-07-29 | 2013-01-07 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Plk阻害剤の塩 |
WO2021194320A1 (en) * | 2020-03-27 | 2021-09-30 | Uppthera | Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012101029A1 (en) * | 2011-01-26 | 2012-08-02 | Nerviano Medical Sciences S.R.L. | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors |
ES2602791T3 (es) * | 2011-01-26 | 2017-02-22 | Nerviano Medical Sciences S.R.L. | Derivados de pirrolo tricíclicos, proceso para su preparación y su uso como inhibidores de cinasa |
US20190381043A1 (en) | 2018-06-13 | 2019-12-19 | King Faisal Specialist Hospital & Research Centre | Method of Treatment of Cancer |
JP2022511282A (ja) | 2018-08-26 | 2022-01-31 | カーディフ・オンコロジー・インコーポレイテッド | Plk1標的のリン酸化状態及びplk1阻害剤を用いた癌の治療 |
CN113631224A (zh) * | 2019-02-25 | 2021-11-09 | 凯帝夫肿瘤科技有限公司 | 用于抑制平滑肌的非肾上腺素能收缩和前列腺细胞增殖的onvansertib |
WO2020198281A1 (en) * | 2019-03-28 | 2020-10-01 | Cardiff Oncology, Inc. | Plk1 inhibitors and psa levels in prostate cancer |
US11957677B2 (en) | 2021-10-15 | 2024-04-16 | Cardiff Oncology, Inc. | Cancer treatment using FGFR inhibitors and PLK1 inhibitors |
WO2023158514A1 (en) * | 2022-02-18 | 2023-08-24 | Massachusetts Institute Of Technology | Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization |
TW202404636A (zh) | 2022-04-08 | 2024-02-01 | 美商英伊布里克斯公司 | Dr5促效劑及plk1抑制劑或cdk抑制劑之組合療法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008074788A1 (en) * | 2006-12-21 | 2008-06-26 | Nerviano Medical Sciences S.R.L. | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1251850B1 (en) * | 2000-01-26 | 2006-06-21 | Schering Corporation | Use of a combination preparation in cancer therapy |
AU2003239511A1 (en) * | 2003-05-20 | 2004-12-13 | Aronex Pharmaceuticals, Inc. | Combination chemotherapy comprising a liposomal platinum complex |
PL1636236T3 (pl) * | 2003-05-22 | 2014-02-28 | Nerviano Medical Sciences Srl | Pochodne pirazolochinazoliny, sposób ich wytwarzania oraz ich zastosowanie jako inhibitory kinaz |
-
2010
- 2010-05-20 AR ARP100101754A patent/AR076784A1/es unknown
- 2010-05-21 US US13/321,024 patent/US8927530B2/en active Active
- 2010-05-21 JP JP2012512317A patent/JP5785157B2/ja active Active
- 2010-05-21 EP EP10723967.5A patent/EP2435041B1/en active Active
- 2010-05-21 WO PCT/EP2010/057027 patent/WO2010136394A1/en active Application Filing
- 2010-05-21 ES ES10723967.5T patent/ES2617689T3/es active Active
- 2010-05-24 TW TW099116481A patent/TW201107327A/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008074788A1 (en) * | 2006-12-21 | 2008-06-26 | Nerviano Medical Sciences S.R.L. | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011505403A (ja) * | 2007-12-04 | 2011-02-24 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 置換ジヒドロプテリジン−6−オン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用 |
JP2013500299A (ja) * | 2009-07-29 | 2013-01-07 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Plk阻害剤の塩 |
WO2021194320A1 (en) * | 2020-03-27 | 2021-09-30 | Uppthera | Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1 |
KR102313752B1 (ko) | 2020-03-27 | 2021-10-19 | (주) 업테라 | Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물 |
Also Published As
Publication number | Publication date |
---|---|
TW201107327A (en) | 2011-03-01 |
JP5785157B2 (ja) | 2015-09-24 |
AR076784A1 (es) | 2011-07-06 |
EP2435041B1 (en) | 2016-12-28 |
US20120114641A1 (en) | 2012-05-10 |
EP2435041A1 (en) | 2012-04-04 |
CN102448454A (zh) | 2012-05-09 |
US8927530B2 (en) | 2015-01-06 |
ES2617689T3 (es) | 2017-06-19 |
WO2010136394A1 (en) | 2010-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5785157B2 (ja) | Plk1阻害剤および抗腫瘍剤を含む治療組合せ | |
JP5579715B2 (ja) | cdk阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
EP2501385B1 (en) | Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent | |
AU2009221120A1 (en) | Improved antitumoral treatments | |
JP2011520921A (ja) | 抗腫瘍アルカロイドとの併用療法 | |
EP3053578B1 (en) | Combination cancer therapy using azabicyclo compound | |
CZ20023766A3 (cs) | Kombinovaná chemoterapie | |
JP5683462B2 (ja) | オーロラキナーゼ阻害剤および抗増殖剤を含む治療用組み合わせ | |
JP5518062B2 (ja) | オーロラキナーゼ阻害剤および抗悪性腫瘍剤を含む治療用組み合わせ | |
CN102448454B (zh) | 包含plk1抑制剂和抗肿瘤剂的治疗性组合 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130516 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140624 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140919 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150608 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150615 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150714 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150723 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5785157 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |